Alfasigma S.p.A.
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 10 disclosed transactions, Alfasigma S.p.A. concentrates its licensing activity in Gastroenterology, Immunology, and Metabolic. Alfasigma S.p.A. pays a 1.50x premium over market median. Their most common deal structure is License, with an average disclosed value of $449M. Most recent activity: 2026.
Pipeline coverage & gaps
Alfasigma S.p.A. has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 6 | $153M | $377M |
| Acquisition | 4 | $524M | $556M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | linerixibat | GSK | cholestatic pruritus in primary biliary cholangitis | phase_3 | $300M | $690M |
| 2026 | Linerixibat | GSK | Primary Biliary Cholangitis (PBC) / pruritus | phase_3 | $300M | $590M |
| 2026 | linerixibat | GSK | primary biliary cholangitis (PBC) - itching | phase_3 | $300M | $690M |
| 2024 | gerd | Phathom Pharmaceuticals | gerd | approved | $450M | $450M |
| 2023 | Jyseleca (filgotinib) | Galapagos | rheumatoid arthritis | approved | $53M | $180M |
| 2023 | Ocaliva (OCA) acquisition | Intercept Pharmaceuticals | PBC (approved), NASH | approved | $794M | $794M |
| 2023 | Ocaliva (obeticholic acid) | Intercept Pharmaceuticals | Primary Biliary Cholangitis (PBC) | approved | $800M | $800M |
| 2021 | bentracimab | PhaseBio Pharmaceuticals, Inc. | reversal of antiplatelet effects of ticagrelor in major bleeding and urgent surgery | phase_3 | $20M | $245M |
| 2019 | Brilacidin | Innovation Pharmaceuticals | ulcerative proctitis/proctosigmoiditis | phase_2 | $400,000 | $24M |
| 2019 | Brilacidin | Innovation Pharmaceuticals | ulcerative proctitis/ulcerative proctosigmoiditis | phase_2 | $400,000 | $24M |
How this is computed
For each Alfasigma S.p.A. deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 3.047, clamped to [0.7, 1.5].